(UroToday.com) The treatment landscape in the first-line therapy of metastatic renal cell carcinoma (mRCC) has rapidly evolved over the past 3 years. While the proliferation of treatment options has provided ample treatment choice, deciding among these can be difficult. In a presentation at the European International Kidney Cancer 2021 Virtual Annual Meeting, Dr. Brian Rini presented on how to choose between VEGF + immune checkpoint inhibition or combined immune checkpoint inhibition with ipilimumab and nivolumab.